- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01428505
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
A Study to Characterize the Novel TSPO PET Radioligand [18F]PBR111 as an in Vivo Marker of Microglial Activation in Multiple Sclerosis
Study Overview
Detailed Description
Multiple Sclerosis is characterized by brain areas of focal neuroinflammation. Imaging of microglia activation in multiple sclerosis could represent a useful marker of neuroinflammation. A novel PET tracer with high affinity to TSPO, [18F]PBR111, is a promising tool for PET imaging of activated microglia.
This is a study aimed to characterize [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of [18F]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple sclerosis and up to 24 age- and gender- matched healthy volunteers. A subgroup of patients and healthy volunteers will be scanned twice in consecutive days, to test the reproducibility of the measure. Another subgroup of patients will be re-scanned with [18F]PBR111 after 4-6 months. MRI-based measures will be acquired at baseline and, in those patients with later repeat PET scans, also after 4-6 months.
Data from this study will inform about the possible implementation of the [18F]PBR111 ligand to monitor the neuroinflammatory process, disease progression, and response to treatment in MS patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W12 0NN
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female, aged 20-70
- Able to read, comprehend and record information written in English.
- Capable of giving written informed consent
- Provide a venous blood sample that will be used for genetics research and the in vitro ligand binding assay.
- A female subject is eligible to participate if she is willing to follow contraception guidelines or if she is of non-childbearing potential.
- Male subjects must agree to use one of the contraception methods
MS subjects:
- Clinical or clinical and laboratory supported diagnosis of multiple sclerosis
- EDSS score up to and including 7.5 at screening evaluation
Healthy Volunteers:
1. Healthy control subjects defined as free from clinically significant active disease as assessed by the Principal Investigator from their medical and psychiatric past and present history
-
Exclusion Criteria:
- If female, positive urine pregnancy test
- An estimated glomerular filtration rate (eGFR) of less than 60 ml/kg/1.73m2
- History or presence of a neurological diagnosis
- Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with radiation exposure.
- Family history of cancer (one or more first-degree relative diagnosed before the age of 55).
- Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.
- Any subject the investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities or subject's unwillingness to comply with all study-related procedures).
- Contraindications to MRI scanning
- Any physical abnormality or functional disability which prevents the subject from acquiring a suitable position for scanning.
- History of or suffers from claustrophobia or feels that he will be unable to lie still on his back in the PET camera or MRI scanner for a period of at least 90mins.
- Unwillingness or inability to follow the procedures outlined in the protocol. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: no treatment
|
radioligand to assess binding to TSPO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VT of [18F]PBR111
Time Frame: day 30
|
Regional VT of [18F]PBR111 at baseline in MS patients and age- , gender-, and TSPO binding profile- matched healthy controls
|
day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Test-retest variability of regional [18F]PBR111
Time Frame: 8 months
|
Test-retest variability of regional [18F]PBR111 VT in 2 consecutive days in MS patients and age- ,gender-, and TSPO binding profile- matched healthy controls
|
8 months
|
regional [18F]PBR111 VT
Time Frame: 1.5 years
|
Change in regional [18F]PBR111 VT over ~ 4 months after a baseline assessment in MS patients
|
1.5 years
|
White matter lesion load and distribution
Time Frame: 1.5 years
|
White matter lesion load (volume of pathological tissue) and distribution as measured by Gadolinium-enhanced and T2-weighted MRI in MS patients
|
1.5 years
|
Cortical grey matter lesion load and distribution
Time Frame: 1.5 years
|
Cortical grey matter lesion load and distribution as estimated by the appropriate MRI technique (including high-field MRI in some cases)
|
1.5 years
|
Genetic polymorphisms related to the TSPO gene
Time Frame: 1.5 years
|
Genetic polymorphisms related to the TSPO gene and/or genes encoding other proteins which may modulate the binding of ligands to TSPO or TSPO function
|
1.5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 115241
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on [18F]PBR111
-
Institute for Neurodegenerative DisordersCompletedAlzheimer DiseaseUnited States
-
Universiteit AntwerpenJanssen Research & Development, LLC; Agentschap voor Innovatie door Wetenschap...Completed
-
University of North Carolina, Chapel HillBoston Children's Hospital; Medical College of Wisconsin; National Football LeagueEnrolling by invitation
-
Genentech, Inc.Completed
-
Adam BrickmanNational Institute on Aging (NIA)Completed
-
Chang Gung Memorial HospitalRecruitingProgressive Supranuclear PalsyTaiwan
-
Five Eleven Pharma, Inc.CompletedParkinson DiseaseUnited States
-
Genentech, Inc.Completed
-
Molecular NeuroImagingCompletedAlzheimer Disease | Healthy Volunteers | Progressive Supranuclear PalsyUnited States
-
Washington University School of MedicineRecruiting